The global electrophoresis equipment and supplies market size 2026 was valued at USD 2.35 billion in 2025 and is projected to grow from USD 2.49 billion in 2026 to USD 3.96 billion by 2034, reflecting a compound annual growth rate (CAGR) of 5.95% over the forecast period, according to Fortune Business Insights. Growth is anchored in the expanding role of electrophoresis in molecular biology, clinical diagnostics, genomics, and proteomics, where these systems separate DNA, RNA, and proteins across hospitals, research institutes, and biotech firms. The report notes that more than 64% of molecular biology laboratories depend on electrophoresis techniques for nucleic acid and protein characterization, while automation, high-resolution imaging, and digital data tools are pushing analytical accuracy and lab productivity higher.
The United States leads adoption within this space, supported by a mature biotechnology research base and widespread use of electrophoresis in genomic testing, disease screening, and forensics across more than 71% of advanced molecular diagnostics laboratories.
Regional Distribution
North America commands roughly 39% of the global market, followed by Europe at 28% and Asia-Pacific at 25%, with the remaining 8% spread across the rest of the world. Within Europe, Germany and the United Kingdom hold about 26% and 19% of regional share respectively, while in Asia-Pacific, China (38%) and Japan (22%) represent the largest national markets, driven by expanding genomic research infrastructure and government-backed biotechnology initiatives.
Get a Free Sample PDF - https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/electrophoresis-equipment-and-supplies-market-103095
Segmentation Highlights
By technique, DNA electrophoresis leads with roughly 45% share, owing to its central role in genetic testing, forensics, and sequencing, followed by protein electrophoresis (31%) and RNA electrophoresis (24%), the latter buoyed by mRNA therapeutic and vaccine development. By product, gel electrophoresis remains dominant at approximately 51% share due to its simplicity and affordability, while capillary electrophoresis follows at 32% on the strength of automation and high-throughput capability; supplies and accessories such as reagents, gels, and buffers account for about 17%. By end-user, biotechnology and pharmaceutical companies represent the largest segment at 48%, ahead of diagnostic centers (29%) and academic and research institutes (23%).
Market Drivers, Restraints, and Opportunities
Rising demand for genomics and molecular diagnostics is the principal growth driver, with more than 67% of modern diagnostic laboratories now using electrophoresis for DNA analysis and mutation detection. Conversely, high instrument costs and ongoing maintenance requirements pose a constraint, with around 39% of small diagnostic labs citing budget limitations for premium systems. The expansion of personalized medicine and proteomics research presents a significant opportunity, as roughly 54% of biotechnology organizations increase investment in protein characterization and biomarker workflows. A persistent challenge remains workflow standardization, since over 33% of technicians report variability tied to manual gel preparation and staining.
Trends and Innovation
Automation, miniaturization, and digital integration define the current trend landscape. Close to 58% of biotechnology labs are shifting toward automated electrophoresis platforms to cut manual error, while microfluidic systems are gaining traction for faster processing with lower reagent use. Fluorescence-based detection is now used by nearly 46% of protein analysis labs, and new product launches increasingly feature cloud connectivity and AI-assisted imaging, with about 49% of recent product introductions incorporating digital workflow tools.
Competitive Landscape
Key players named in the report include Thermo Fisher Scientific, Bio-Rad Laboratories, Agilent Technologies, PerkinElmer, Merck KGaA, Beckman Coulter, Hoefer, Lonza Group, SERVA Electrophoresis, C.B.S Scientific, QIAGEN, and Helena Laboratories. Thermo Fisher Scientific and Bio-Rad Laboratories lead the competitive field with approximately 19% and 16% market share respectively. Recent moves include Thermo Fisher's 2024 expansion of automated capillary electrophoresis solutions, Bio-Rad's 2025 launch of AI-assisted gel imaging systems, and QIAGEN's 2024 expansion of RNA workflow solutions for transcriptomics research.
Outlook
Fortune Business Insights frames the market's trajectory as closely tied to continued investment in precision medicine, biologics manufacturing, and genomic testing infrastructure, with emerging economies in Asia-Pacific and the rest of the world expected to contribute increasing shares of demand as laboratory modernization continues. The convergence of automation, microfluidics, and AI-assisted analysis is expected to remain the central theme shaping product development through 2034.